SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CACCIARI, Barbara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.214
AS - Asia 4.597
EU - Europa 2.535
SA - Sud America 847
AF - Africa 50
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 18.249
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.037
SG - Singapore 1.660
CN - Cina 1.514
BR - Brasile 709
UA - Ucraina 688
DE - Germania 500
TR - Turchia 469
HK - Hong Kong 449
GB - Regno Unito 339
VN - Vietnam 281
SE - Svezia 231
IT - Italia 185
FI - Finlandia 178
RU - Federazione Russa 148
MX - Messico 90
FR - Francia 79
CA - Canada 74
PL - Polonia 61
AR - Argentina 53
IN - India 49
ID - Indonesia 34
EC - Ecuador 31
ZA - Sudafrica 28
BD - Bangladesh 26
NL - Olanda 22
BE - Belgio 21
JP - Giappone 21
PY - Paraguay 17
ES - Italia 16
LT - Lituania 13
IQ - Iraq 12
PK - Pakistan 12
AT - Austria 10
CO - Colombia 9
MA - Marocco 8
VE - Venezuela 8
CL - Cile 7
IE - Irlanda 7
PE - Perù 7
SA - Arabia Saudita 7
AE - Emirati Arabi Uniti 6
TW - Taiwan 6
UZ - Uzbekistan 6
CZ - Repubblica Ceca 5
IR - Iran 5
JO - Giordania 5
KZ - Kazakistan 5
AL - Albania 4
AZ - Azerbaigian 4
BG - Bulgaria 4
KR - Corea 4
NP - Nepal 4
PA - Panama 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
CH - Svizzera 3
EG - Egitto 3
KG - Kirghizistan 3
PT - Portogallo 3
TN - Tunisia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AU - Australia 2
BO - Bolivia 2
BY - Bielorussia 2
DK - Danimarca 2
KE - Kenya 2
LB - Libano 2
LV - Lettonia 2
MD - Moldavia 2
ME - Montenegro 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PH - Filippine 2
PS - Palestinian Territory 2
RO - Romania 2
RS - Serbia 2
SY - Repubblica araba siriana 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
DZ - Algeria 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
GP - Guadalupe 1
HN - Honduras 1
KH - Cambogia 1
KW - Kuwait 1
MG - Madagascar 1
MK - Macedonia 1
NI - Nicaragua 1
NO - Norvegia 1
PR - Porto Rico 1
SD - Sudan 1
TH - Thailandia 1
Totale 18.249
Salva come PNG Salva come JPEG
Città #
Woodbridge 977
Ashburn 939
Singapore 935
Fairfield 914
Dallas 849
Houston 776
Jacksonville 712
Chandler 593
Ann Arbor 488
Hong Kong 445
Santa Clara 418
Beijing 379
Seattle 363
Wilmington 358
Cambridge 264
Nanjing 243
Izmir 220
Princeton 158
Los Angeles 113
Boardman 112
San Diego 89
Ho Chi Minh City 86
Shenyang 77
Nanchang 67
São Paulo 67
Munich 62
Dong Ket 61
Hefei 60
Mexico City 59
New York 53
Warsaw 52
Hanoi 48
Shanghai 45
Ferrara 43
Milan 43
Jiaxing 41
Tianjin 41
San Mateo 37
Falkenstein 34
Hebei 34
Brooklyn 33
Kunming 32
Changsha 31
Jinan 31
Zhengzhou 31
Chicago 30
Dearborn 30
Helsinki 29
London 27
Falls Church 26
San Francisco 24
Philadelphia 23
Norwalk 22
Rio de Janeiro 22
Brussels 21
Moscow 21
Orem 20
Tokyo 20
Frankfurt am Main 19
Montreal 19
Ningbo 19
Turku 19
Chennai 18
Toronto 18
Addison 17
Buffalo 17
Guangzhou 17
Jakarta 17
Phoenix 17
Stockholm 17
Bremen 14
Denver 14
Istanbul 14
Johannesburg 14
Mountain View 14
Taizhou 14
The Dalles 14
Amsterdam 13
Manchester 13
Verona 13
Curitiba 12
Montréal 12
Redwood City 12
Atlanta 11
Boston 11
Indiana 11
Poplar 11
Porto Alegre 11
Salvador 11
Washington 11
Augusta 10
Ankara 9
Charlotte 9
Da Nang 9
Guayaquil 9
Mcallen 9
Orange 9
Auburn Hills 8
Baghdad 8
Brasília 8
Totale 12.380
Salva come PNG Salva come JPEG
Nome #
1,2,3-triazolo[5,4-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: A new class of A(2A) adenosine receptor antagonists 1.126
[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid inhibits DNA binding to transcription factor Sp1 481
1-methyl-3-nitro-5-methoxycarbonyl pyrazole 259
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors 222
6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors 209
1H-pyrazolo[2,3-d][1,2,4]triazine-3,7-diones as a new class of human leukocyte elastase inhibitors 201
Synthesis, in vitro antiproliferative activity, and DNA-binding properties of hybrid molecules containing pyrrolo[2,1-c][1,4] benzodiazepine and minor-groove-binding oligopyrrole carriers 186
A new synthetic approach to indazole synthesis 181
8-(2-Furyl)adenine derivatives as A₂A adenosine receptor ligands 180
Design, synthesis, in vitro antiproliferative activity and apoptosis-inducing studies of 1-(3',4',5'-trimethoxyphenyl)-3-(2'-alkoxycarbonylindolyl)-2-propen-1-one derivatives obtained by a molecular hybridisation approach 180
[H-3]MRE 3008F20: A novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors 177
7-substituted-5-amino-2-(furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: importance of modifications at the side chain on the activity and solubility. 175
5-heteroarylcarbamoylamino-pyrazolo-triazolo pyrimidines as hA3 adenosine receptor antagonists. 174
7-substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A(2A) adenosine receptor antagonists: A study on the importance of modifications at the side chain on the activity and solubility 174
Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists 164
1H-pyrazolo[4,3-d]pyrimidine-7(6H)-one and 5H-pyrazolo[4,3-d] 1,2,3-triazin-4(3H)-one derivatives. Synthesis and in vitro biological activity at adenosine A1 and A2a receptors 163
Resolution of a CPzI precursor, synthesis and biological evaluation of (+) and (-)-N-Boc-CPzI: A further validation of the relationship between chemical solvolytic stability and cytotoxicity 161
New potent and selective human adenosine A3 receptor antagonists. 161
Antiproliferative effects of novel synthetic nucleobase analogues on U937 Histiocytic lymphoma cell line 160
Schematic overview of oligosaccharides, with survey on their major physiological effects and a focus on milk ones 160
Solid lipid microparticles for the stability enhancement of a dopamine prodrug 159
Synthesis and antitumor activity of novel distamycin derivatives 158
The influence of the 1-(3-Trifluoromethyl-Benzyl)-1H-Pyrazole-4-yl moiety on the adenosine receptors affinity profile of pyrazolo[4,3-e][1,2,4]Triazolo[1,5-c] pyrimidine derivatives 155
[3H]-MRE 3008-F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. 154
DNA minor groove alkylating agents structurally related to distamycin A 152
[3H]MRE3008-F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A3 adenosine receptors. 151
7-sobstituted-5-amino-2-(furyl)-pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonist: importance of modifications at the side chain on the activity and solubility. 150
Synthesis and calcium antagonist activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(nitrogenous heteroaryl)-3,5-pyridine dicarboxylates. 150
New potent and selective human adenosine A3 receptor antagonists 149
Synthesis and antitumor activity of a new class of pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone analogs of pyrrolo[1,4]benzodiazepines (PBDs) 148
Oligonucleotides and oligonucleotide conjugates: A new approach for cancer treatment 147
A2A-adenosine receptor reserve for coronary vasodilation 145
A(1) and A(3) adenosine receptor agonists: an overview 143
Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors 142
Synthesis and properties of substituted CBI analogs of CC-1065 and the duocarmycins incorporating the 7-methoxy-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (MCBI) alkylation subunit: Magnitude of electronic effects on the functional reactivity 142
Carbon nanotube substrates boost neuronal electrical signaling 142
Synthesis and Biological Evaluation of a New Series of 1,2,4-Triazolo[1,5-a]-1,3,5-triazines as Human A(2A) Adenosine Receptor Antagonists with Improved Water Solubility 141
DNA minor-groove binders: results and design of new antitumor agents 140
Nitrile oxide [3 + 2] cycloaddition: application to the synthesis of 6-substituted 3(2H)-pyridazinones and 6-substituted 4,5-dihydro-4-hydroxy-3(2H)-pyridazinones 139
An efficient procedure for the synthesis of 5H-6-substituted-pyrazolo[1,5-d]-1,2,4-triazine-4,7-diones 138
Ethyl (R,S)-5-acetyl-4,5-dihydro-3-isoxazoleacetate 138
Structure-activity relationship of novel tallimustine derivatives: Synthesis and antitumor activity 137
Ethyl-(R,S)-5-acetyl-4,5-dihydro-3-isoxazole acetate 137
Design, synthesis and biological activity of a pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid 136
New 9-methyl-8-(4-hydroxyphenyl)adenine derivatives as A1 adenosine receptor antagonists 136
Structure Activity Relationship of 4-Amino-2-thiopyrimidine Derivatives as Platelet Aggregation Inhibitors 136
Recent developments in the field of adenosine receptor ligands 135
Selective binding to human genomic sequences of two synthetic analogues structurally related to U-71184 and adozelesin 135
Synthesis and Antitumor Activity of a New Class of Pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone Analogs of Pyrrolo[1,4][2,1-c]benzodiazepines 134
Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo- pyrimidine antagonists binding site of the human adenosine A2A receptor 131
Facile and versatile route to the synthesis of fused 2-pyridones: Useful intermediates for polycyclic sytems 131
Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c] [1,4]benzodiazepines 131
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: A complete structure-activity profile 130
Chemical Synthesis of [13C]Daidzein 130
A novel class of pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as A3 adenosine receptor antagonists 130
Pyrazolo-triazolo-pyrimidines as adenosine receptor antagonists: Effect of the N-5 bond type on the affinity and selectivity at the four adenosine receptor subtypes 129
Synthesis and preliminary biological evaluation of [H-3]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A(3) adenosine receptors 127
The Significance of 2-Furyl Ring Substitution with a 2-(para-substituted) Aryl Group in a New Series of Pyrazolo-triazolo-pyrimidines as Potent and Highly Selective hA3 Adenosine Receptors Antagonists: New Insights into Structure-Affinity Relationship and Receptor-Antagonist Recognition 127
Synthesis and biological evaluation of new antitubulin agents containing 2-(30,40,50-trimethoxyanilino)-3,6-disubstituted-4,5,6,7-tetrahydrothieno[2,3-c]pyridine Scaffold 126
A(3) adenosine receptor ligands: History and perspectives 125
Cosmetic preservation and structure-activity relationships of 4-diazo-pyrazole-5-carboxamides 125
Synthesis, biological studies and molecular modeling investigation of 1,3-dimethyl-2,4-dioxo-6-methyl-8-(substituted) 1,2,3,4-tetrahydro [1,2,4]-triazolo [3,4-f]-purines as potential adenosine receptor antagonists 125
Synthesis of pyridazine derivatives through the unexpected intermediate 5-amino-4-cyano-2,3-dihydro-furan-2,3-disulfonic acid disodium salt 123
Unusual Ring-Opening Reaction of 6,7-Dihydrothieno[3,2-d]pyrimidine- 2,4-dione Derivatives Leading to 5-(Alkylthio)-6-vinyluracils 123
Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists 122
CC-1065 and the duocarmycins: recent developments 121
Carbon Nanotubes Carrying Cell-Adhesion Peptides do not Interfere with Neuronal Functionality 121
Exploring Potency and Selectivity Receptor Antagonist Profiles Using a Multilabel Classification Approach: The Human Adenosine Receptors as a Key Study 120
Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors 120
Pyridazine nucleus: a pharmacophoric moiety for bio-active compounds 118
null 118
Demystifying the three dimensional structure of G protein-coupled receptors (GPCRs) with the aid of molecular modeling 116
Pyrazolo [4,3-E]1,2,4-triazolo[1,5-c]pyrimidine derivates a new class of potent and selective human A3 adenosine receptor antagonists. 115
Substituted 6-amino-thiouracils as new P2Y(12) receptor antagonists 114
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: Potent and selective A2A adenosine antagonists 113
Novel N-6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A(3) adenosine receptors 112
A Novel Conjugated Agent between Dopamine and an A(2A) Adenosine Receptor Antagonist as a Potential Anti-Parkinson Multitarget Approach. 112
Comparative molecular field analysis (CoMFA) of a series of selective adenosine receptor A(2A) antagonists 109
Synthesis and cardiodepressant activity of dialkyl 1,4-dihydro-2,6-dimethyl-4-(pentatomic-heteroaryl)-3,5-pyridinedicarboxylates. 2 108
Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process 107
Synthesis and Biological Activity of a New Series of N6-Arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-Carboxamido Derivatives of Adenosine-5'-N-ethyluronamide as A1 and A3 Adenosine Receptor Agonists 107
Synthesis and Biological Evaluation of Highly Active 7-Anilino Triazolopyrimidines as Potent Antimicrotubule Agents 107
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]-pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists 106
Synthesis and molecular investigation of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivates as human A3 adenosine receptor antagonists. 105
Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: Irreversible antagonists at the human A(3) adenosine receptor and molecular modeling studies 105
null 104
Synthesis, biological and modeling studies of new water soluble hA3 adenosine receptor antagonists. 104
Conjugation of Dopamine and an A2A Adenosine Receptor Antagonist: a possible approach for the treatment of Parkinson’s Disease. 104
Synthesis and molecular investigation of new pyrazolo[4,3-e]1,2,4,-triazolo[1,5-c]pyrimidine derivates as human A3 adenosine receptor antagonists. 104
Synthesis, antibacterial activity and structure-activity relationships of N-substituted 4-diazopyrazole-5-carboxamides. 2 102
Heterocyclic analogs of DNA minor groove alkylating agents 101
Synthesis of the tritium labeled SCH 58261, a new non-xanthine A(2A) adenosine receptor antagonist 101
Synthesis, binding and thermodynamic studies of new highly selective A2A adenosine receptor antagonists 101
Current developments of A(2a) adenosine receptor antagonists 100
A2Aadenosine receptor antagonists as therapeutic candidates: Are they still an interesting challenge? 99
Rationale design of new human adenosione A3 receptor antagonists through a CoMFA model. 98
Synthesis, antiviral and antiproliferative activity of a new class of 5-(alkyl or arylthio)-6-vinyl uracils 98
Synthesis, cytotoxicity and antitumor activity of some new simplified pyrazole analogs of the antitumor agent CC-1065. Effect of an hydrophobic group on antitumor activity 97
Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist 97
Binding affinity of adenosine receptor agonists and antagonists at human A3 adenosine receptors 97
Totale 14.859
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.113
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 471
Totale 84.584
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.007 0 0 0 0 0 167 32 199 36 188 232 153
2021/20221.361 39 138 78 135 85 51 42 83 38 98 153 421
2022/20231.317 158 63 26 171 220 223 31 118 173 8 73 53
2023/2024810 70 92 34 21 71 60 20 260 12 12 10 148
2024/20252.595 75 134 196 79 329 171 55 201 395 316 379 265
2025/20264.569 660 559 1.299 1.011 901 139 0 0 0 0 0 0
Totale 18.370